Lupin Ramps Up Strategy to Counter U.S. Tariff Threat, Posts 52% Profit Surge
Mumbai, August 7, 2025 — Indian pharmaceutical giant Lupin is drawing up a multi-pronged strategy to navigate the looming threat of U.S. tariffs, while celebrating a robust 52% year-on-year surge…
Lupin to boost complex generics in US, EU; eyes chronic growth in India
Lupin, which plans to develop the specialty business, is eyeing higher revenue share from its complex generics portfolios in the US and Europe. Moreover, with a pipeline of over 200…
Lupin receives US FDA Establishment Inspection Report for Somerset facility
Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset, New Jersey.…